VISEN Pharmaceuticals (02561) Reports January 2026 Monthly Return on Equity Movements
Bulletin Express
Feb 03
VISEN Pharmaceuticals (02561) published a monthly return on equity movements for the period ended 31 January 2026. The authorised share capital remained unchanged at 500,000,000 ordinary shares, each with a par value of USD 0.0001, for a total of USD 50,000. The number of issued shares stayed at 113,926,864, and there were no treasury shares at the end of January 2026.
No changes were reported under share options, warrants, convertibles, or any other arrangements to issue shares. Under the Post-IPO Share Award Scheme, there were no new issuances during the month, leaving the total number of shares unchanged. The public float requirement, set at 25% of issued shares excluding treasury shares, remained in compliance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.